Clinical Trial List for Cancer Research (Breast Cancer) in all locations

1. Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane Adjuvant Therapies for Pre-Menopausal Women with Endocrine Responsive Breast Cancer (IBCSG 24-02)

1. Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer (IBCSG 25-02)

1. Comparison of Types of Radiation Techniques for Women with Early Stages of Breast Cancer (B-39)

1. Genetics Study for Women with Breast Cancer and Starting Anastrozole (Arimidex) Treatment (MC0532)

1. Treatment with Examestane, an Aromatase Inhibitor, versus Placebo, for Postmenopausal Women at High Risk for Developing Breast Cancer (MAP 3)

1. Bisphosphonates as Treatment in Breast Cancer (S0307)

1. N063D/BIG 2-06, ALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study - A randomised, multi-centre, open-label,phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer

1. Phase II Study of Paced Breathing for Hot Flashes

1. Estrogen-DNA Adducts in Breast, Urine and Serum (Blood) as Biomarkers of Breast Cancer Risk

1. Z1031, A Phase 3 Trial Comparing 16 to 18 Weeks of Neoadjuvant (Given Before Surgery) Exemestane (25 mg daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women with Stage 2 and 3 Estrogen Receptor Positive Breast Cancer

1. Combined Chemotherapy and Hormone Therapy for Individuals with a Low Risk of Cancer Recurrence after Ten Years: The TAILORx Trial

1. 06-213 A Phase 2 Study of Lapatinib (Tykerb) in Combination with Trastuzumab (Herceptin) in Patients with HER2-Positive, Metastatic Breast Cancer

1. Phase III Study of Cyclophosphamide (Cytoxan) and Doxorubicin (Adriamycin) (CA) (4 Cycles) Versus Paclitaxel (Taxol) (4 Cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes